ERBB2 and breast cancer: This increase in AKT phosphorylation and decrease in MAPK/MEK phosphorylation in response to lapatinib may act as a sensitivity biomarker for refametinib in HER2-positive breast cancer cell lines, whereby cells which signal primarily through the MAPK pathway are most sensitive to MEKi such as refametinib.